Cardiovascular Health

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events and reduced visits to their physician or cardiologist.

Increasing dietary potassium, such as from bananas, may lower blood pressure more effectively than reducing sodium alone.

Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).

The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

Individuals with cognitive and physical disabilities faced difficulties in health care utilization and had reduced rates of preventive cardiovascular screenings during the pandemic.

FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years old.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

In children and adolescents with overweight and obesity, exercise was demonstrated to reduce risk factors associated with cardiovascular disease, such as lipid and triglyceride levels.

Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.

Discover effective strategies for managing obesity to enhance cardiovascular health, including innovative treatments and the vital role of pharmacists.

Promoting heart health in children reduces obesity and chronic disease risks, ensuring better overall well-being into adulthood.

In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).

By targeting aldosterone in a 2-dose regimen, baxdrostat effectively lowers mean seated systolic blood pressure in patients with difficult-to-treat hypertension.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

Results from the ZENITH trial show sotatercept's promise for pulmonary arterial hypertension treatment.